Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Completed · Phase 1

Conditions studied: Colorectal Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody F19 in treating patients who have advanced or metastatic cancer.

Key facts

Study ID

NCT00004042

Run by

Memorial Sloan Kettering Cancer Center

People needed

24

Starts

1998-11-01

Expected to finish

2009-12-01

Last updated by the study team

2013-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Ludwig Institute for Cancer Research-Sydney Branch — Sydney, New South Wales, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.